Logo

GALT

Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc. • NASDAQ
$5.73 ▼ -0.52% (-0.03)
Market Cap $368.93 M
52w High $6.55
52w Low $0.73
Dividend Yield 0%
P/E -9.71
Volume 73.28K
Outstanding Shares 64.39M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.198M ▼ $-8.184M ▼ 0% $-0.13 ▼ $-6.364M ▼
Q2-2025 $0 $4.623M ▼ $-7.521M ▲ 0% $-0.12 ▲ $-5.693M ▲
Q1-2025 $0 $7.887M ▼ $-9.631M ▲ 0% $-0.15 ▲ $-7.877M ▲
Q4-2024 $0 $12.418M ▲ $-11.967M ▼ 0% $-0.19 ▼ $-10.232M ▼
Q3-2024 $0 $9.057M $-11.22M 0% $-0.18 $-9.717M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $11.525M ▼ $12.865M ▼ $138.168M ▲ $-125.303M ▼
Q2-2025 $13.771M ▲ $15.602M ▲ $132.769M ▲ $-117.167M ▼
Q1-2025 $7.431M ▼ $9.528M ▼ $121.789M ▲ $-112.261M ▼
Q4-2024 $15.12M ▼ $17.495M ▼ $120.565M ▼ $-103.07M ▼
Q3-2024 $27.06M $28.972M $121.453M $-92.481M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.184M ▼ $-3.542M ▲ $0 $1.296M ▼ $-2.246M ▼ $-3.542M ▲
Q2-2025 $-7.521M ▲ $-6.602M ▲ $0 $12.942M ▲ $6.34M ▲ $-6.602M ▲
Q1-2025 $-9.631M ▲ $-7.689M ▲ $0 $0 ▼ $-7.689M ▲ $-7.689M ▲
Q4-2024 $-11.967M ▼ $-12.791M ▼ $0 $851K ▼ $-11.94M ▼ $-12.791M ▼
Q3-2024 $-11.22M $-8.538M $0 $10M $1.462M $-8.538M

Five-Year Company Overview

Income Statement

Income Statement Galectin has remained a pure research company, with no product sales and therefore no recurring revenue. Its income statement is driven almost entirely by research and overhead costs. Losses have been steady and fairly small in absolute terms, but they have persisted year after year, and per‑share losses have gradually worsened. This pattern is typical for a clinical‑stage biotech: the business is essentially a cost center until a drug is approved or partnered on attractive terms.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of assets, mostly cash. Debt has grown from almost nothing to a more meaningful level, while the company’s equity has slipped from positive into negative territory. That shift into negative equity signals that accumulated losses and borrowing now outweigh the asset base. Overall, the balance sheet looks thin and increasingly reliant on creditors and future financing rather than on internally generated value so far.

Cash Flow

Cash Flow Cash flows show a consistent pattern of cash being used, not generated. Operating cash flow has been modestly negative each year, reflecting ongoing spending on trials and operations without any offsetting income. There is virtually no spending on physical assets, so total cash use closely mirrors the operating burn. This means the company relies heavily on outside funding to refill the cash balance, and cash runway and future capital access remain key watchpoints.

Competitive Edge

Competitive Edge Galectin is operating in a crowded but important area: metabolic liver disease and fibrosis, plus some oncology combinations. Its main edge is focus: it targets patients with advanced liver disease and cirrhosis, where treatment options are limited and competition is thinner than in early‑stage fatty liver disease. The company also benefits from a long patent runway and a differentiated mechanism—galectin‑3 inhibition—where only a few players are active. At the same time, it competes indirectly with much larger firms that already have approved drugs in earlier disease stages, and its commercial position will hinge on whether late‑stage data are strong enough to stand out and secure regulatory and payer support.

Innovation and R&D

Innovation and R&D Innovation is clearly the heart of the company. Belapectin, its lead drug, uses a carbohydrate‑based approach to block galectin‑3, aiming to halt or slow fibrosis and improve outcomes in advanced liver disease. Early signals in liver disease, cancer combinations, and inflammatory skin conditions suggest a broad platform rather than a single narrow asset. The platform also appears to have practical advantages, such as potentially favorable safety and scalable manufacturing. However, the company is still in the clinical trial phase, with mixed top‑line results in its key liver study and heavy dependence on partnerships and funding to push further into oncology and next‑generation, more convenient formulations. R&D progress is promising but remains high‑risk and unproven at a commercial scale.

Summary

Galectin is a classic high‑risk, high‑uncertainty clinical‑stage biotech: no revenue, ongoing losses, and a thin balance sheet offset by a focused, innovative technology platform. Financially, the company is dependent on external capital, with growing debt and negative equity underscoring the importance of future financings or partnerships. Strategically, its niche in advanced liver cirrhosis and its novel galectin‑3 mechanism give it a differentiated story in an important disease area, with additional optionality in cancer and inflammatory conditions. The ultimate outcome will depend on the strength and reproducibility of clinical data, regulatory feedback on belapectin, and Galectin’s ability to secure partners and funding to turn scientific promise into a sustainable business.

NEWS

November 14, 2025 · 8:00 AM UTC

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

Read more

September 2, 2025 · 8:00 AM UTC

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Read more